Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Eksp Klin Gastroenterol ; (12): 4-12, 2014.
Artículo en Ruso | MEDLINE | ID: mdl-26058105

RESUMEN

Hepatitis delta (HD) is characterized by rapid progression to fibrosis, and development of hepatocellular carcinoma, and a high mortality rate. The article presents data on the epidemiology, diagnosis, treatment of HD. The views of the epidemiological, clinical and virological characteristics of HD-infection among population of the Russian Federation (RF) are limited due to absence of official HD registration and detection of antibodies to the HD virus (anti-HDV) in HBsAg-positive individuals. However, some areas of the country are characterized by a high HDV circulation (Republic Tyva (RT) - 46,5%, Republic Sakha (Yakutia) - 12,5%) according to our studies conducted in 6 regions of Russia. Clinical-epidemiological situation of HDV infection in RT can be considered as a model to create a program of optimize diagnosis, prevention and treatment of HDV-infection in the Russian Federation.


Asunto(s)
Hepatitis D/epidemiología , Virus de la Hepatitis Delta/inmunología , Anticuerpos Antivirales/sangre , Antivirales/administración & dosificación , Antivirales/efectos adversos , Antivirales/uso terapéutico , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Hepatitis D/terapia , Hepatitis D/virología , Virus de la Hepatitis Delta/efectos de los fármacos , Humanos , Trasplante de Hígado , ARN Viral/sangre , Federación de Rusia/epidemiología , Replicación Viral/efectos de los fármacos
2.
Vaccine ; 20(1-2): 170-80, 2001 Oct 12.
Artículo en Inglés | MEDLINE | ID: mdl-11567762

RESUMEN

The cellular immune response is a crucial defense mechanism against hepatotropic viruses and in chronic viral hepatitis prevention. Moreover, hepatitis delta virus (HDV) immunogenicity may be an important component in the development of prophylactic and therapeutic vaccines. Therefore, we evaluated the immunogenicity of the small (HDAg) or large delta antigen (LHDAg) to be used as a DNA-based vaccine. We immunized different mouse haplotypes, determined cellular immune responses, and tested protection of animals against tumor formation using syngeneic tumor cells stably expressing the delta antigens. Both LHDAg and HDAg primed CD4+ and CD8+ T cell immunity against both forms of delta antigens. CD8+ T cell frequencies were about 1% and antigen-specific CD8+ T cells remained detectable directly ex vivo for at least 35 days post-injection. No anti-delta antibody responses could be detected despite multiple detection systems and varied immunization approaches. We observed protection against syngeneic tumor formation and growth in mice immunized with DNA plasmids encoding secreted or intracellular forms of HDAg and LHDAg but not with recombinant HDAg establishing the generation of significant cellular immunity in vivo. Both CD4+ and CD8+ T cells were required for antitumoral activity as determined by in vivo T cell depletion experiments. The results indicate that DNA-based immunization with genes encoding LHDAg and HDAg induces strong T cell responses and, therefore, is an attractive approach for the construction of therapeutic and prophylactic T cell vaccines against HDV.


Asunto(s)
Antígenos de la Hepatitis/inmunología , Virus de la Hepatitis Delta/inmunología , Sarcoma de Mastocitos/prevención & control , Linfocitos T Citotóxicos/inmunología , Vacunas de ADN/inmunología , Vacunas Virales/inmunología , Animales , Anticuerpos Antivirales/análisis , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Línea Celular , Citotoxicidad Inmunológica , Virus Defectuosos/inmunología , Evaluación Preclínica de Medicamentos , Femenino , Vectores Genéticos/administración & dosificación , Vectores Genéticos/genética , Haplotipos , Antígenos de Hepatitis delta , Inmunidad Celular , Interferón gamma/biosíntesis , Activación de Linfocitos , Sarcoma de Mastocitos/inmunología , Sarcoma de Mastocitos/patología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Endogámicos DBA , Músculo Esquelético/citología , Trasplante de Neoplasias , Proteínas Recombinantes/inmunología , Transfección , Células Tumorales Cultivadas/trasplante
3.
Eur J Epidemiol ; 10(6): 657-64, 1994 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-7672043

RESUMEN

In order to assess the interaction between alcohol intake, tobacco smoking and coffee consumption in determining the risk of liver cirrhosis we carried out a hospital-based case-control study involving 115 patients at their first diagnosis of cirrhosis and 167 control patients consecutively enrolled in the General Hospitals of the Province of L'Aquila (Central Italy). The mean life-time daily alcohol intake (as g ethanol consumed daily) was measured by direct patient interviews, whose reproducibility was > 0.80 and similar for cases and controls, as checked by interviewing the relatives of a sample of 50 cases and 73 controls. During the same patient's interview we also measured the mean consumption of coffee (daily number of cups of filtered coffee) and tobacco (life-time daily number of cigarettes smoked). A dose-effect relationship on the risk of cirrhosis was present both for alcohol intake--for which the risk was significantly increased above 100 g of daily intake--and for cigarette consumption. The latter did not however improve the goodness-of-fit of a logistic regression model including alcohol intake as covariate. By contrast, coffee consumption had a protective effect on the risk of cirrhosis and significantly improved the goodness-of-fit of such a model. Abstaining from coffee consumption determined both a significantly increased risk of cirrhosis, even for daily alcohol intake below 100 g, and a multiplicative effect with alcohol intake on this risk. In patients drinking > or = 101 g ethanol daily the relative risk increased from 5.5 (95% confidence interval: 1.4-22.0) for coffee consumers to 10.8 (95% confidence interval: 1.3-58.1) for coffee abstainers.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Consumo de Bebidas Alcohólicas/efectos adversos , Café/efectos adversos , Cirrosis Hepática/etiología , Fumar/efectos adversos , Bebidas Alcohólicas/efectos adversos , Estudios de Casos y Controles , Relación Dosis-Respuesta a Droga , Etanol/administración & dosificación , Femenino , Hepacivirus/inmunología , Anticuerpos Antihepatitis/sangre , Antígenos de la Hepatitis B/sangre , Virus de la Hepatitis Delta/inmunología , Humanos , Italia , Modelos Logísticos , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Factores de Riesgo , Método Simple Ciego
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA